{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.65","value":"62.25"},{"groupId":"OG001","spread":"24.80","value":"65.49"},{"groupId":"OG002","spread":"32.93","value":"37.17"},{"groupId":"OG003","spread":"23.72","value":"57.09"},{"groupId":"OG004","spread":"5.97","value":"65.00"},{"groupId":"OG005","spread":"10.83","value":"49.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumor cells.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG005","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg"}],"paramType":"MEAN","populationDescription":"Safety population included all the participants who received at least one dose of study treatment. Here, \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Part 4: Week 1 end of infusion (EOI)","title":"Part 4: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells","type":"SECONDARY","unitOfMeasure":"Percentage of cells"}